CHPA shares FDA’s concern regarding news reports that teens are challenging each other on social media to misuse and abuse OTC medicines containing diphenhydramine, commonly used for allergy symptoms.
Recognizing the urgent need to address confusion around the legal status of hemp and hemp-derived CBD, we call on Congress to provide FDA statutory authority and additional resources to regulate hemp and hemp-derived CBD as a dietary supplement.
CHPA released the following statement in response to ongoing efforts by the U.S. Food and Drug Administration (FDA) to keep hand sanitizers that contain harmful substances off the market.
The Consumer Healthcare Products Association released the following statement in response to the Trump Administration’s “Buy American” Executive Order (EO) for essential pharmaceuticals.
CHPA released the following statement in response to the CDC Viewpoints article titled, “Prevention of Unintentional Medication Overdose Among Children,” published in the Journal of the American Medical Association.
The Consumer Healthcare Products Association released the following statement in response to the U.S. Food and Drug Administration report to Congress on the current cannabidiol marketplace.
The results of nearly all recent observational studies of patients from around the world diagnosed with COVID-19 show no association between exposure to NSAIDs (including ibuprofen) and worsening clinical outcomes.
CHPA takes pride in the diverse consumer base our industry serves, and we support those who are raising their voices to advocate for a more just and equitable future for our nation.
